Drug intelligence / Profile preview

Criofit

Development stage: Preclinical
Lead developer: Plazma-FTK
Modality: Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical, Local Application

Overview

Criofit is a fibrin-thrombin sealant used in surgical procedures, particularly after autologous breast reconstruction, to reduce seroma incidences and drainage volume. It functions by mimicking the final stage of the natural coagulation cascade, where its components, fibrinogen and thrombin, react to form a stable fibrin clot. This process promotes hemostasis and tissue adhesion, thereby minimizing fluid accumulation and preventing seroma formation post-surgery. The product is developed and manufactured by PLAZMA-FTK.

Brand names: Criofit

Targets

Fibrin (Factor Ia)Coagulation Factor XIII

Beyond the preview

Go deeper on Criofit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Criofit.

Explore the full profile